1970 – MD and PhD, Complutense University of Madrid, Spain.
1971-1974. Postdoctoral training, State University of New York, Downstate Medical Center, New York, USA.
Director: Instituto Teófilo Hernando de I+D del Medicamento (ITH), Facultad de Medicina, Universidad Autónoma de Madrid. Head, Servicio de Farmacología Clínica Hospital Universitario de la Princesa, Facultad de Medicina, Universidad Autónoma de Madrid, Spain.
Exocytosis-neurotransmission-calcium signalling. I am working for near 40 years on basic ionic and receptor mechanisms involved in the regulation of exocytotic neurotransmitter release. I mostly use the adrenal medullary chromaffin cell as a model to perform electrophysiological, pharmacological and neurosecretory studies, combining calcium imaging techniques with patch-clamp and amperometric techniques. I am particularly interested in developing my hypothesis that the functional triad formed by voltage-dependent calcium channels, the endoplasmic reticulum, and mitochondria shape the cytosolic calcium signals required to regulate pre-exocytotic and exocytotic steps. I am trying to project this hypothesis into pathogenic mechanisms of four disorders i.e. Alzheimer´s disease, amyotrophic lateral sclerosis, fetal and perinatal hypoxia and hypertension.
Design, synthesis and Pharmacology of neuroprotective compounds with potential therapeutic application in neurodegeneratives diseases and stroke. In 1994 I published my first paper, trying to link sodium and calcium channels to basic mechanisms of neuronal death, using the chromaffin cell as a model. In subsequent years, I developed this area, focusing on neurotoxicity mechanisms looking for targets to develop new chemical entities with potential neuroprotective actions and therapeutic applications to neurodegenerative deseases (particularly Alzheimer´s disease) and to cerebrovascular diseases (stroke).
Scientific publications (SCI): 370; Hirsch index: 50..